A chewable low-dose oral contraceptive: a new birth control option?
نویسنده
چکیده
A new chewable combined oral contraceptive pill containing ethinyl estradiol (EE) 0.025 mg and norethindrone (NE) 0.8 mg in a 24/4 regimen was approved for marketing in December 2010. Each of the four inactive tablets contains 75 mg ferrous fumarate, which has no therapeutic benefit. The tablet can be taken with food but not water as this affects the absorption of EE. The Pearl index based on intention to treat women aged 18-35 years has been reported at 2.01 (confidence interval [CI] 1.21, 3.14) and for the whole population 1.65 (CI 1.01, 2.55). The effect of a body mass index of >35 was not studied. Regular withdrawal bleeding occurred for 78.6% of women in Cycle 1, but by Cycle 13 almost half the women failed to have a withdrawal bleed. This new formulation provides an intermediate dose of an EE/NE combination that will be useful for women experiencing breakthrough bleeding on the lower-dose EE/NE pill. The convenience of a low-dose pill, which can be chewed without the need for water, will be useful to enable women who have forgotten a pill to take one whenever they remember, provided they carry it with them. The advantage of a 24/4 regimen is better suppression of follicular development in the pill-free interval and may be beneficial for women who experience menstrual cycle-related problems, such as heavy bleeding or dysmenorrhea.
منابع مشابه
New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control
AIM To review milestones in development of oral contraceptive pills since their introduction in the US 50 years ago in order to better understand how a new formulation with low-dose estrogen in an extended-cycle pattern fits into the evolution of birth control pills. METHODS This is a review of trends in the development of various birth controls pills and includes data from phase III clinical...
متن کاملRecent Advances in Hormonal Contraceptives for Women
Currently, Contraceptive agents play a key role in family planning in India. Hormonal contraception is the marketed most common birth control option in women. An estimated 100 million women throughout the world use hormonal contraceptives for prevention of pregnancy. This article briefly describes the recent advances in hormonal contraceptive strategies that may minimize side effects while opti...
متن کاملIn vitro and in vivo interaction of oral contraceptive high dose (HD) with urine morphine diagnostic test
Introduction: Urine morphine test, in several countries is the most primarily available qualitative test for detecting opioid abusers. Since the users of illicit drugs attempt to defeat urine tests and there are also plenty of claims that usage of HD (high dose) contraceptive pills can result in false-negative results, we decided to design the present study to investigate the probable in vit...
متن کاملThe association between current low-dose oral contraceptive pills and periodontal health: a matched-case-control study.
AIM This study assessed the influence of current oral contraceptive pills on periodontal health in young females. METHODS AND MATERIALS Seventy women ranging in age from 17 to 35 years (mean 24 years) had a comprehensive periodontal examination. Their current and previous oral contraceptive pill use was assessed by a questionnaire. A periodontal assessment was performed that included recordin...
متن کاملNatazia®: a New Combination Oral Contraceptive
JALYN® (DUTASTERIDE/TAMSULOSIN): A NEW OPTION IN BPH n the U.S., the leading method of contraception is the combination oral contraceptive pill. More than 10 million women aged 15-44 years use the birth control pill as their primary method of contraception.1 Since the first BCP approval in 1960, the FDA has approved many oral contraceptive products. Most of these products use ethinyl estradiol ...
متن کامل